IgA nephropathy update and European collaborative research in this glomerulonephritisVídeňská 1958/9, Prague 4, Czech Republic
Prague Czech Republic
April 13-14, 2012
Institute of Clinical and Experimental Medicine, Vídeňská 1958/9, Prague 4, Czech Republic
Czech Society of Nephrology in collaboration with EUROPEAN VALIDATION STUDY OF THE OXFORD CLASSIFICATION OF IGA NEPHROPATHY coordinator, Rosanna Coppo, Regina Margherita Hospital, Pediatric Nephrology, University of Turin. Italy and ERA-EDTA Continual Medical Education Working Group.
Local Coordinator/Contact Person for information:
Prof. Vladimir Tesar, Email: firstname.lastname@example.org; email@example.com
IgA nephropathy the most common glomerular disease worldwide, is potentially progressive to renal failure. In individual patients its course is unpredictable before development of severe proteinuria, hypertension, reduced glomerular filtration rate and renal fibrosis. There is a need to detect progressive cases in early stages, when a therapeutic intervention is more likely to be effective. Recent genetics and immunologic studies had provided relevant data which can be useful as risk factors for disease progression. The role of pathological lesions has been recently pointed out by a report from an International Consensus, based on a retrospective analysis of 265 adults and children with IgAN from four continents. According to this Oxford Classification of IgAN, four pathological features (mesangial hypercellularity, segmental glomerulosclerosis, endocapillary hypercellularity, and tubular atrophy/interstitial fibrosis) predict renal outcome independently from all clinical indicators at the time of biopsy and during follow up (Kidney International 2009;76:534-45; and Kidney International 2009;76:546-56). The limited number of patients and their heterogeneous origin indicated a need for validation studies involving larger cohorts of patients. VALIGA was planned to investigate European IgA nephropathy patients also in order to gather results complementary to those from similar studies in North America and Asia, allowing a global perspective on the value of these factors to predict the clinical outcome of patients with IgA Nephropathy.At August 25th, 2011, the VALIGA Study includes 52 Centers of Nephrology and Renal Pathology from 13 European Countries (Croatia, Czech Republic, Estonia, Germany, Greece, Italy, Poland, Portugal, Spain, Sweden, The Netherlands, Turkey, United Kingdom) with a total of 1215 cases enrolled. 964 cases are completed (both clinical spreadsheets and pathology scoresheet review were received) of which 805 renal biopsy slides were sent to Oxford for final review.This multicenter, multinational study supported by the ERA-EDTA will provide information beyond the validation of the Oxford classification of IgAN, aiming at detecting for each lesion the “point of no return” when no treatment is effective. The material gathered is outstanding and it could offer the possibility of new investigations in the field. The aim of the meeting is to provide the participants with the recent progress in the genetics,pathogenesis and histologic classification of IgA nephropathy. Clinical and histology cases will be discussed inthe meet the expert sessions.
Scientific content of the educational event:
A high level scientific update will be given in the following area of IgA nephropathy
Lectures (30 minutes + 30 minute discussion)
1) Genetics of sporadic and familial cases : A.Gharavi, New York, Columbia University
2) IgA aberrant glycation : J Novak, Birmingham, USA
3) Value of pathology features : I Roberts, Oxford, UK
4) Meet the expert: How to manage a 1000 patients data-base : S. Troyanov, Canada
5) Meet the expert Clinical cases discussion. V Tesar, R.Coppo, J Feehally
6) Meet the expert Pathology cases discussion T.Cook , London, UK, Eva Honsova, Prague
7) Meet the expert Future of research in IgA nephropathy
To apply for travel grant please click here.
Click here to download the course programme.